definitely shtf a bear market makes it virtually impossible for a stinky pinky to operate our shares will be almost worthless. now is the time to
strike pick-up a revenue producer or go under with the xall holdings
that have been producing miniscule revenue lately.

the inflation axe is about to drop so very important xall picks up a decent revenue producing cos asap

https://nypost.com/2022/02/11/goldman-sachs-predicts-fed-will-hike-rates-7-times-in-2022/

if xall price is tanked it will be harder to do acq. i get your point though.

xalles does have a solid management with sales talent hoping one of them closes a deal.

https://xalles.com/management/

looks like we wait for the next tweet from the tweet master.

The Funko NFT trend is growing worldwide

https://usa.inquirer.net/93079/funko-nft-trend?utm_source=push_notification

looks like xall may shift money from the $849,000 showing in investments held from quarter ending sept 30,2021 since little revenue has been generated from recent operations?

so far xall o/s has stayed the same next update will be the tell.

xall o/s update on 02/07 no change
1,172,751,609
02/07/2022
Restricted
711,641,609
02/07/2022
Unrestricted
461,110,000
02/07/2022

what i was thinking too xall should have more revenue.

i figured his shot to have revenue would be with intel365 ? here is to hoping.

hoping for decent revenue from recent acq. intel365


http://intel365.net/

i sure hope xalles produced decent revenue so we all do well here!

i like the way slimjim thinks !i too mentioned before about flag possibly coughing up some of that money to xall?

we will see soon enough.xall has a pretty big nut now with the management payroll so they need to produce.

iam thinking there should be good xalles news especially concerning their management team and some good results.

https://xalles.com/management/

nice bid support xall 1,250,000 at .0068

is xall doing a lazarus we will soon find out hopefully ?

xall last few trades of today



Time Price Volume Market
15:59:49 0.0084 12000 OTCBB
15:59:49 0.008 20000 OTCBB
15:59:46 0.0078 100000 OTCBB
15:58:05 0.0078 20000 OTCBB
15:55:49 0.0078 16207 OTCBB
15:53:01 0.0075 83793 OTCBB
15:52:42 0.0075 100000 OTCBB

my tda showing xall closed at .0084 hope its correct?

check and see whether dr patterson has a vial of leronlimab in his shirt pocket[as was mentioned once] but most likely nader cut him off.

no endpoint for fibrosis reduction was mentioned in the madrigal data
maybe a big difference advantage for leronlimab?

statement by nader re nash:

"Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique drug with tremendous opportunities.”

fda really put the screws to cydy no wonder they went to brazil for their covid trial.looking like we should get some results soon and i have a hunch
they will be vastly improved.

cd-12 mortality benefit is 31 % above soc. if you have any evidence or proof in a documentation to disprove this please show.

maybe cd-12 failed the p value but still with 2 doses was 31% better than soc. i never saw a retraction of this press release or other.

https://www.cytodyn.com/newsroom/press-releases/detail/533/cytodyn-to-submit-newly-completed-topline-report-of-cd12

nash results supposedly very good so we await proof ?

i agree lets hope they can get the car out of the ditch so to speak. hope they refile their tnbc cancer i believe we can put a nice dent into the trodelvy business no side effect factor should play big,by all means pursue
their brazil trial to show that on 4 doses in their covid trial we should be closer to 80% better than soc rather than on the 2 doses in cd-12 31% better than soc,and the longhauler study .

not sure cytodyn is a done deal quite yet but they did get themselves in a bit of a pickel now.

will be interesting to see how sidley handles matters here.

quite a no nonsense list very well done.

Reclassifications

Certain prior year and prior quarter amounts shown in the accompanying Consolidated Financial Statements have been reclassified to conform to the current period presentation. These reclassifications did not have any effect on the Company’s financial position, results of operations, stockholders’ (deficit) equity, or net cash flows as previously reported.

nader is gone but he did say he would resubmit TNBC results with an extended date far better than trodelvy.we will see what they do or able to do at this time.not holding my breath until i see a plan.

i read all the 10-q 2 am last night saw this part about the sec.bottom line cydy needs to show all data and it better be factual.wont deny cydy has a hill to climb on the finance front though.wonder if they are allowed to sell those shares as restricted?

The Company has received subpoenas from the United States Securities and Exchange Commission (“SEC”) and the United States Department of Justice (“DOJ”) requesting documents and information concerning, among other matters, leronlimab, the Company’s public statements regarding the use of leronlimab as a potential treatment for COVID-19, HIV, and triple-negative breast cancer, related communications with the FDA, investors, and others, litigation involving former employees, the Company’s retention of investor relations consultants, and trading in the Company’s securities. Certain Company executives have received subpoenas concerning similar issues and may be interviewed by the DOJ or SEC in the future. The SEC informed the Company that its inquiry should not be construed as an indication that any violations of law have occurred or that the SEC has any negative opinion of any person, entity or security.

i noticed that director mr naydenov did a warrant exchange and kicked in $700,000 for shares to help. really nice of mr naydenov.


On September 23, 2021, Jordan G. Naydenov, a member of the Company’s Board of Directors, entered into a private warrant exchange in which he exercised warrants to purchase approximately 0.6 million shares of common stock, as well as approximately 0.6 million additional shares that were offered as an inducement to exercise his warrants, for a total of approximately 1.3 million shares of common stock. The terms and conditions of the investment totaling approximately $0.7 million made by Mr. Naydenov were identical to those offered to other investors. See also Note 12 below.

trodelvy appears to be the new soc in TNBC[with all the side effects] but leronlimab beat it by 3 months .not good enough for the fda. would love to read all the data.

https://www.cytodyn.com/newsroom/press-releases/detail/574/cytodyn-announces-cancer-update-12-month-analysis-of-28

i believe you have the facts all wrong there will be an investigation into all the shorting ,maybe naked,that took place 06/30/2020 by the citron report which was hastily then removed after the damage was done.more than just citron was involved in this effort too.the biggest deal with nader
is many did not like his 3 fingers routine in a proactive.but from the time i first bought shares cydy nov.2019 many just did not like nader period .




BioInvestor4 Tuesday, 06/30/20 02:40:50 PM
Re: None 0
Post #
89094
of 199065
Tim Sykes bragging and congratulating his followers on Twitter about the orchestrated short attack on CYDY today....

not necessarily a done deal the order also states

IT IS FURTHER ORDERED that Amarex’s motion to dismiss is denied as moot.
IT IS FURTHER ORDERED that any party may move to re-open the case for the purpose of addressing compliance with the Preliminary Injunction Order or to terminate the Preliminary Injunction Order.

Plaintiff, v. AMAREX CLINICAL RESEARCH, LLC, and NSF INTERNATIONAL, INC. Defendants.

STIPULATED ORDER OF DISMISSAL OF NSF AND ADMINISTRATIVE CLOSURE WITHOUT PREJUDICE AND WITHOUT COSTS
Pursuant to this Court’s Order entered on January 18, 2022 [Dkt. 43] granting the Joint Stipulation by the parties [Dkt. 42] and associated agreement of the parties for dismissal of NSF International, and based on further stipulation of the parties to administratively close the entire of this matter; IT IS HEREBY ORDERED that Defendant NSF International identified in the complaint as “NSF International, Inc.” is dismissed without prejudice and without costs to either party.
IT IS FURTHER ORDERED that the remainder of the case as to claims against Defendant Amarex Clinical Research, LLC (“Amarex”) is administratively closed and the parties will resolve all claims (including Plaintiff’s request for attorneys’ fees and costs) in the pending arbitration.
IT IS FURTHER ORDERED that this Court’s Preliminary Injunction Order [Dkt. 35 as modified in Dkts. 42 and 43] the “Preliminary Injunction Order” remains in place, including the requirement that CytoDyn post the bond as set forth therein and file the bond with the Court which the Clerk of the Court shall accept for filing after this order and the requirements, both conditioned on posting of the bond, that Amarex provide CytoDyn with the trial master files and cooperate with an independent audit.
IT IS FURTHER ORDERED that Amarex’s motion to dismiss is denied as moot.
IT IS FURTHER ORDERED that any party may move to re-open the case for the purpose of addressing compliance with the Preliminary Injunction Order or to terminate the Preliminary Injunction Order.
IT IS SO ORDERED. Hon. Peter J. Messitte U.S. District Court Judge Approved as to form on January 28, 2022: SIDLEY AUSTIN LLP HOWARD & HOWARD ATTORNEYS PLLC /s/Benjamin Mundel /s/Patrick M. McCarthy By: Benjamin Mundel
By: Patrick M. McCarthy Counsel for Plaintiff CytoDyn, Inc. Counsel for Defendants NSF International and Amarex Clinical Research, LLC

thats what the doctor on my "remdesivir and other treatments" thread on twitter was saying in washington d.c. but of course it was deleted how convenient. all this witch-hunt against cydy is because leronlimab is superior.most all of the drugs bp is putting out has side effects.

"WHO recommends against the use of remdesivir in COVID-19 patients. WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.Nov 20, 2020"

your obfuscation of the facts is amazing since just about all covid hospital patients are routinely given remdesivir especially medicare patients. gilead has a good racket going i take my hat off to them.

leronlimab for covid even cd-12 only 2 doses after 2 weeks at 82% better than placebo destroys remdesivir. go watch melon toy testimonial on youtube saved from covid by leronlimab look no side effects but for a little pain prick from the needle injection.many other people like her too saved by leronlimab.